This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.01.063v1 47/11/2172    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiménez-Quevedo, P. Search for Related Content PubMed PubMed Citation Articles by Jiménez-Quevedo, P.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients

Three-Dimensional Ultrasound Results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial

Pilar Jiménez-Quevedo, MD^_*,1, Manel Sabaté, MD, PhD^_*,_*, Dominick J. Angiolillo, MD, Marco A. Costa, MD, PhD, Fernando Alfonso, MD, PhD^_*, Joan Antoni Gómez-Hospital, MD, PhD, Rosana Hernández-Antolín, MD, PhD^_*, Camino Bañuelos, MD^_*, Javier Goicolea, MD, PhD, Francisco Fernández-Avilés, MD, PhD^||, Theodore Bass, MD^_*,,,,||, Javier Escaned, MD, PhD^_*, Raul Moreno, MD^_*, Cristina Fernández, MD, PhD^_*, Carlos Macaya, MD, PhD^_* for the DIABETES Investigators

^_* San Carlos University Hospital, Madrid, Spain
University of Florida Cardiovascular Imaging Core Laboratories, Jacksonville, Florida
"Prínceps d’Espanya" University Hospital, Barcelona, Spain
"Do Meixoeiro" University Hospital, Vigo, Spain
^|| Clínico University Hospital, Valladolid, Spain

Manuscript received October 31, 2005; revised manuscript received December 29, 2005, accepted January 16, 2006.

^_* Reprint requests and correspondence: Dr. Manel Sabaté, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. (Email: manelsabate1{at}telefonica.net).

OBJECTIVES: A predefined intravascular ultrasound (IVUS) substudy was performed to evaluate the vascular effects of sirolimus-eluting stent (SES) versus bare-metal stent (BMS).

BACKGROUND: The Diabetes and Sirolimus-Eluting Stent (DIABETES) trial is a prospective, multicenter, randomized, controlled trial aimed at demonstrating the efficacy of the SES compared with BMS in diabetic patients.

METHODS: Serial intravascular ultrasound analyses were performed in 140 lesions (SES = 75; BMS = 65) immediately after stent implantation and at nine-month follow-up. Vessel, luminal, and stent mean areas and volumes were evaluated at both edges and within the stented segment. Qualitative assessment of residual dissections and stent apposition were also performed.

RESULTS: Baseline clinical and angiographic characteristics were similar between groups. At 9 months, in-stent neointimal hyperplasia (NIH) mean area and volume were significantly reduced in the SES group (median NIH area 0.01 mm² [0.0 to 0.1] vs. 2.0 mm² [1.0 to 2.9] and median NIH volume 0.11 mm³ [0 to 2.1] vs. 35.3 mm³ [16.6 to 62.6]; both p < 0.0001). In the SES group, stent edges evidenced significant increase in lumen dimensions mainly due to significant increase in vessel volume, whereas those of the BMS group presented vessel shrinkage leading to significant lumen reduction. Late acquired incomplete stent apposition was observed in 11 lesions (14.7%) in the SES group and 0 in the BMS group (p = 0.001). At one year, no stent thromboses occurred in malapposed stents.

CONCLUSIONS: The SES implantation effectively inhibits NIH in diabetic patients. The antirestenotic effect of SES is also appreciated at the stent edges. Late acquired stent malapposition is a frequent phenomenon in diabetic patients treated with SES.

Abbreviations and Acronyms   BMS = bare-metal stent   DIABETES = Diabetes and Sirolimus-Eluting Stent trial   EEM = external elastic membrane   ISA = incomplete stent apposition   IVUS = intravascular ultrasound   NIH = neointimal hyperplasia   SES = sirolimus-eluting stent

This article has been cited by other articles:

				L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial Eur. Heart J., November 2, 2008; 29(22): 2733 - 2741. [Abstract] [Full Text] [PDF]

				E. Camenzind, P. G. Steg, and W. Wijns Response to Letter Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern" Circulation, October 16, 2007; 116(16): e390 - e390. [Full Text] [PDF]

				P. Jimenez-Quevedo, M. Sabate, D. J. Angiolillo, F. Alfonso, R. Hernandez-Antolin, M. SanMartin, J. A. Gomez-Hospital, C. Banuelos, J. Escaned, R. Moreno, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial Eur. Heart J., August 2, 2007; 28(16): 1946 - 1952. [Abstract] [Full Text] [PDF]

				D. R. Holmes Jr Coming close and then pulling away Eur. Heart J., June 1, 2007; 28(11): 1275 - 1276. [Full Text] [PDF]

				E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]